

R&D Pipeline

Development Code	Brand Name (Country/Region)	Generic Name	Drug Class (Formulation)
Metabolic (Diabetes and Obesity)			
AD-4833	Actos (Japan, US, Europe, Asia)	pioglitazone	Insulin sensitizer (Oral)
SYR-322	Nesina (Japan)	alogliptin benzoate	DPP-4 inhibitor (Oral)
	Contrave®	naltrexone SR/bupropion SR	μ opioid receptor antagonist and dopamine/norepinephrine re-uptake inhibitor (Oral)
ATL-962		cetilistat	Lipase inhibitor (Oral)
SYR-472		Not decided	DPP-4 inhibitor (Oral)
TAK-428		Not decided	Neurotrophic factor production accelerator (Oral)
TAK-875		Not decided	GPR40 agonist (Glucose-dependent insulin secretagogue) (Oral)
AC137-164594		pramlintide/metreleptin	Synthetic amylin analog/Synthetic leptin analog (Injection)
TAK-329		Not decided	Glucokinase activator (Oral)

Oncology

	Mepact (Europe)	mifamurtide	Synthetic analog of muramyl dipeptide (Injection)
	VELCADE® (US)	bortezomib	Proteasome inhibitor (Injection)
	Vectibix® (Japan)	panitumumab	Human monoclonal antibody (MAb) against the human EGFR (Injection)
	Prednisolone (Japan)	prednisolone	Adrenal corticosteroid (Oral)
TAK-700		Not decided	Non-steroidal androgen synthesis inhibitor (Oral)
AMG 706		motesanib diphosphate	VEGFR1-3 inhibitor (Oral)
SGN-35	ADCETRIS™	brentuximab vedotin	CD30 monoclonal antibody - drug conjugate (Injection)
AMG 386		Not decided	Anti-angiopoietin peptibody (Injection)
AMG 479		ganitumab	Human monoclonal antibody agonist human type 1 insulin-like growth factor receptor (IGF-1R) (Injection)
MLN0518		tandutinib	Inhibitor of receptor kinases (FLT-3, PDGFR, c-KIT) (Oral)
MLN8237		Not decided	Aurora A kinase inhibitor (Oral)
MLN9708		Not decided	Proteasome inhibitor (Oral/Injection)
TAK-448		Not decided	Metastin analog (Injection)
TAK-733		Not decided	MEK inhibitor (Oral)
TAK-960		Not decided	PLK1 inhibitor (Oral)
TAK-901		Not decided	Aurora B kinase inhibitor (Injection)
MLN4924		Not decided	NEDD 8 activating enzyme inhibitor (Injection)
TAK-441		Not decided	Hedgehog signaling pathway inhibitor (Oral)
AMG 655		conatumumab	Human monoclonal antibody agonist directed against DR5 (TRAIL-R2) (Injection)
TAK-701		Not decided	HGF-antibody (Injection)

Associated Information → P.40 R&D Pipeline/Major Pipeline Drugs Offering Potential as Next-Generation Core Products

Indications/Type	Country/ Region	Stage of Development				
		Phase I	Phase II	Phase III	NDA Submission	NDA Approval
Fixed-dose combination with metformin	Japan					2010.04
Fixed-dose combination with glimepiride	Japan					2011.01
Diabetes mellitus	US					*1
	Japan					2010.04
	Indonesia					2011.01
	Taiwan					2011.03
	Europe					
Diabetes mellitus (Fixed-dose combination with Actos)	US					*2
	Japan					2011.07
	Europe					
Diabetes mellitus (Concomitant therapy with α -GI)	Japan					2010.04
Diabetes mellitus (Concomitant therapy with thiazolidinediones)	Japan					2010.08
Diabetes mellitus (Concomitant therapy with Sulfonylurea)	Japan					2011.02
Diabetes mellitus (Concomitant therapy with Biguanide)	Japan					2011.02
Diabetes mellitus (Fixed-dose combination with metformin)	US					
	Europe					
Obesity	US					*3
Obesity	Japan					
Diabetes mellitus	US					
	Europe					
	Japan					
Diabetic neuropathy	US					
	Europe					
Diabetes mellitus	US					
	Europe					
	Japan					
Obesity	US					※Suspended
Diabetes mellitus	—					

Non-metastatic osteosarcoma	Mexico					2010.12
Relapsed follicular lymphoma	US					2011.02
Front line mantle cell lymphoma	US					
Subcutaneous formulation	US					2011.03
Relapsed diffuse large B cell lymphoma	US					
Squamous cell carcinoma of head and neck	Japan					
Multiple myeloma	Japan					2011.01
Prostate cancer	US					
	Europe					
	Japan					
Advanced non-squamous non-small cell lung cancer	US					
	Europe					
	Japan					
Breast cancer	US					
Relapsed or refractory Hodgkin's lymphoma	Europe					2011.05
Relapsed or refractory systemic anaplastic large cell lymphoma	Europe					2011.05
Hodgkin's lymphoma (First-line indication)	Europe					
Systemic anaplastic large cell lymphoma (First-line indication)	Europe					
Recurrent ovarian cancer	Japan					
Metastatic pancreatic cancer	Japan					
Glioblastoma	US					
Aggressive non-Hodgkin's lymphoma, Acute myelogenous leukemia, High risk myelodysplastic syndrome, Ovarian cancer	US					
	Europe					
Progressive cancer	Japan					
Multiple myeloma	US					
Advanced malignancies	US					
Prostate cancer	—					
Solid tumors	—					
Solid tumors	—					
Advanced malignancies	—					
Advanced malignancies	—					
Solid tumors	—					
Progressive cancer	Japan					
Advanced malignancies	—					

*1 FDA Complete Response Letter received (2009.06) *2 FDA Complete Response Letter received (2009.09) *3 FDA Complete Response Letter received (2011.01)
As of July 1, 2011